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Thulium Oxide Nanoparticles: A new candidate for image-guided radiotherapy 
Abstract 
Nanoparticles, with their distinct properties that vary from their bulk material equivalent, continue to gain 
popularity for studies into multi-modal applications in medicine. This research introduces the use of 
thulium oxide nanoparticles for biological applications and characterizes the potential of this novel 
nanoparticle for image-guided radiotherapy of brain cancer. In this study, we investigate the structural 
characteristics of this nanoparticle, and reveal a significant dose enhancement towards radioresistant 
brain tumour cells in vitro that also underlies an improvement in the CT image contrast of brain tumours 
in vivo. The thulium oxide nanoparticles utilized in the investigations described in this article were 
measured to be 40–45 nm from x-ray diffraction and scanning electron microscopy data. In vitro 
investigations assessed the cell survival and DNA damage in 9 l gliosarcoma cells following irradiation 
with 150 kVp orthovoltage x-rays. Immediately after the 150 kVp irradiation (15 min) an increase in the 
number of γ-H2AX induced foci indicates the production of more double-strand DNA breaks. Following 
from the short time-frame irradiation outcomes, clonogenic cell survival assays confirmed long-term 
radio-sensitization, with the cell sensitivity increasing by a factor of 1.32 (measured at the 10% survival 
fraction) for the irradiated 9 l cells exposed to thulium nanoparticles. A simple CT experiment shows that 
our thulium nanoparticles suspended in water at concentrations >0.5 mg ml−1 (0.05–20 mg ml−1 
investigated) are clearly observable against water. Extending the CT experiment to an in vivo 
investigation, cellular uptake of the nanoparticles was demonstrated through CT image enhancement of 
the cancer site in 9- to 10-week-old Fisher rats bearing 9 l gliosarcomas, 12 days after cell implantation. 
The 9 l cancer is clearly visible on the CT image after injecting 40 μg of nanoparticles (2 μl at 20 mg ml−1) 
directly to the cancer site (5.5 mm from the dura and 3.5 mm right laterally of the bregma, 5 mm depth). 
To our knowledge, this work demonstrates the first application of thulium nanoparticles in biology and 
medicine, for radiotherapy and image guidance purposes. 
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ABSTRACT 13 
Nanoparticles, with their distinct properties that vary from their bulk material equivalent, 14 
continue to gain popularity for studies into multi-modal applications in medicine. This 15 
research introduces the use of thulium oxide nanoparticles for biological applications and 16 
characterizes the potential of this novel nanoparticle for image-guided radiotherapy of 17 
brain cancer. In this study, we investigate the structural characteristics of this 18 
nanoparticle, and reveal a significant dose enhancement towards radioresistant brain 19 
tumour cells in vitro that also underlies an improvement in the CT image contrast of brain 20 
tumours in vivo. The thulium oxide nanoparticles utilized in the investigations described in 21 
this article were measured to be 40-45 nm from X-ray diffraction and scanning electron 22 
microscopy data. In vitro investigations assessed the cell survival and DNA damage in 9L 23 
gliosarcoma cells following irradiation with 150 kVp orthovoltage X-rays. Immediately 24 
after the 150 kVp irradiation (15 min) an increase in the number of γ-H2AX induced foci 25 
indicates the production of more double-strand DNA breaks. Following from the short 26 
time-frame irradiation outcomes, clonogenic cell survival assays confirmed long-term 27 
radio-sensitization, with the cell sensitivity increasing by a factor of 1.32 (measured at the 28 
10% survival fraction) for the irradiated 9L cells exposed to thulium nanoparticles. A 29 
simple CT experiment shows that our thulium nanoparticles suspended in water at 30 
concentrations >0.5 mg/mL (0.05 – 20 mg/mL investigated) are clearly observable against 31 
water. Extending the CT experiment to an in vivo investigation, cellular uptake of the 32 
nanoparticles was demonstrated through CT image enhancement of the cancer site in 9- to 33 
10-week-old Fisher rats bearing 9L gliosarcomas, 12 days after cell implantation. The 9L 34 
cancer is clearly visible on the CT image after injecting 40 μg of nanoparticles (2 µL at 20 35 
mg/mL) directly to the cancer site (5.5 mm from the dura and 3.5 mm right laterally of the 36 
bregma, 5 mm depth). To our knowledge, this work demonstrates the first application of 37 
thulium nanoparticles in biology and medicine, for radiotherapy and image guidance 38 
purposes  39 
 40 









































































Brain and central nervous system (CNS) cancers are the leading cause of cancer-related death in 42 
children under the age of 10 (Australian Institute of Health and Welfare, 2017). While the 5-year 43 
survival rates for most cancers continue to improve, brain and CNS cancers have remained at 44 
25% in Australia. These cancers often consist of highly radio-resistant cells, sub-categorized 45 
further as gliomas and glioblastomas (Kelley et al 2016). Gliomas represent approximately 30% 46 
of all cancers and 82% of malignant tumours in young adults, and yet survival for patients with 47 
brain cancer does not exceed 52% (Ostrom et al 2015). 9L gliosarcoma is an animal cell model 48 
similar to high-grade human glioma cells and shows a strong resistance to X-ray irradiation 49 
(Malaise et al 1986). 9L is the most widely used of all rat brain tumour models for research as 50 
well as a preclinical model used in brain radiotherapy and has been utilized in various treatment 51 
studies for over 30 years (Barth 1998). 52 
In developed countries, radiation is used to treat half of all cancer patients (Baskar et al 2012).  53 
Photons generated by linear accelerators and X-ray tubes can be used to treat a broad range of 54 
tumours from deep-seated cancers to tumours on the surface of the skin, respectively. The 55 
success of cancer treatment with radiation depends on the total radiation dose delivered to a 56 
tumour and the tolerance of surrounding normal tissues (Barnett et al 2009). Radiation-induced 57 
damage occurs either directly or indirectly due to the production of ionising electrons and 58 
reactive oxygen species (ROS) respectively. The cellular response to radiation differs markedly 59 
however, due to location, function and more specifically, the repair mechanisms employed by the 60 
cell to correct radiation damage. 61 
Equally important to the success of cancer treatment is the capability to image cancers, both for 62 
diagnosis and radiotherapy treatment planning purposes. Computed tomography (CT) is by far 63 
the most popular imaging modality that uses kilovoltage X-rays to contrast denser tissues against 64 
regions of lower density (Goldman, 2007). To help distinguish between tissues, contrast agents 65 
containing iodine (Z=53), are commonly used clinically. For well-vascularized tumour sites, 66 
contrast enhancement in tumours is possible. The passive uptake of iodinated molecules into 67 
tumours relies then on the vascularization and blood brain barrier permeability, location and 68 
hypoxic nature of the cells (Lusic et al 2013). 69 
Nanoparticles ranging in size from 1 to 100 nm have gathered popularity for biological 70 
applications because their size allows them to pass easily into living cells, as well as their wide 71 
range in functionality (Hainfield et al 2004, 2008, Haume et al 2016, Maggiorella et al 2012, 72 
Retif et al 2015, Sinharay et al 2016). The field of nanomedicine extends to radiotherapy and 73 
diagnostic imaging, where high-Z nanoparticles are favoured for radiation technologies due to 74 
the strong Z-dependence of many photon interactions (Hainfeld et al 2008, Retif et al 2015). 75 
These nanoparticles produce more secondary electrons, auger electrons, ROS species, and 76 
characteristic X-rays that induce even more localized ionising radiation damage to cells and lead 77 
to radiosensitization. For use in the biological environment, biocompatibility and preferential 78 
cancer cell uptake also become useful properties for nanoparticle radio-sensitising agents. 79 
Nanomaterials which are the most commonly studied for use in radiotherapy or radiology 80 
include gold (Z=79). (Hainfeld et al 2008, Haume et al 2016, Retif et al 2015), hafnium (Z=72), 81 





































































(Maggiorella et al 2012), and gadolinium (Z=64), (Kotb et al 2016), with many supporting 82 
reports on the success of these nanoparticles to increase local dose enhancement in tumours 83 
using kilo-voltage and mega-voltage radiation fields, with strong dependence on nanoparticle 84 
size, concentration, distribution, and beam energy. 85 
Additional properties have been reported for nano-structured ceramics or metal oxide materials 86 
such as cerium oxide, bismuth oxide and tantalum oxide nanoparticles. Cerium oxide 87 
nanoparticles (Z= 58) have the unique ability to both radio-protect and radio-sensitize tumour 88 
cells depending on beam energy (Briggs et al 2013). Bismuth (Z= 83) oxide nanoparticles show 89 
selective toxicity towards radioresistant gliomas (Bogusz et al 2014, Stewart et al 2016) and 90 
tantalum oxide (Z=73) nanoparticles exhibit preferential uptake into tumours, low toxicity, a 91 
unique ordering around the cell nucleus, and are shown to radio-sensitize glioma cells (Brown et 92 
al 2014, 2016, McKinnon et al 2016, McDonald et al 2018). High-Z tantalum pentoxide 93 
nanoparticles produce a sensitivity enhancement ratio (SER) at 10% surviving fraction of 1.33 ± 94 
0.07 with both mega voltage (Brown et al 2014) and kilovoltage (Brown et al 2016) treatments.  95 
Aside from radiotherapy, high-Z nanoparticle materials such as gold (Ashton et al 2015 and 96 
McQuaid et al 2016), gadolinium (Sinharay et al 2016, Lohrke et al 2016) and bismuth oxide 97 
(Bogusz et al 2014, Stewart et al 2016) are shown to be successful candidates for imaging 98 
techniques such as computed tomography. Circulation half-lives have been reported to be 15 99 
hours for high-Z nanoparticles, whereas iodine-based molecules half-lives dissipate within 100 
minutes (Ashton et al 2015). 101 
Lanthanide nanoparticles commonly used for image-guidance include gadolinium. Gadolinium-102 
based nanoparticles have been used in patients since 1988 for Magnetic Resonance Imaging 103 
(MRI) (Lohrke et al 2016) and researched for CT since 1980 (Havron et al 1980). With strong 104 
potential for many imaging and therapeutic modalities, these nanoparticles are now gaining 105 
popularity for image-guided radiotherapy. AGuIX®, a gadolinium-based nanoparticle, is one 106 
candidate that has now reached clinical trials (Maggiorella et al 2012).  107 
There are however, some concerns over the toxicity of some gadolinium-based agents. The 108 
chance of nephrogenic systemic fibrosis (NSF), a potentially fatal disorder in patients with renal 109 
disease, was first linked directly to gadolinium-based contrasts in 2006.  The primary categories 110 
of gadolinium-based nanoparticles are macrocyclic and linear.  Macrocyclic structures encase 111 
gadolinium within complex cavities, which results in a more stable system, less likely to release 112 
free gadolinium to the body (Rogosnitzky et al 2016). The linear form has caused some concern 113 
recently due to the lower stability of this gadolinium-based agent in the body, prompting a 114 
removal from market in Europe (European Medicines Agency, 2017). Due to this, the potential 115 
of new paramagnetic nanoparticles for applications in imaging and radiotherapy must now be 116 
considered. 117 
Thulium is a rare earth metal that has no known biological application to date. Thulium presents 118 
a higher atomic number than gadolinium (Z=69) and exhibits paramagnetic properties (Koehler 119 
et al 1962), which could lead to applications in CT and magnetic resonance imaging 120 
respectively.   121 







































































Thulium is used predominately in lasers, (in this case created by bombarding thulium-169 in a 122 
nuclear reactor with neutrons to make a portable radiation source), and it is gaining popularity 123 
for the surgical treatment of benign prostate obstructions from 2005 (Barbalat et al 2016). 124 
Thulium-based or thulium doped nanoparticles exist in bio-photonics field with potential 125 
applications in luminescent nanothermometers, high resolution bio-imaging, and hyperthermia 126 
for diagnosis and therapy of diseases (Heiligtag and Niederberger 2013, Pereira et al 2017).  127 
Thulium oxide is less frequently studied; however there are some noted applications of thulium 128 
oxide in X-ray devices, phosphors, atomic reactors, medicine, and semiconductors (Sidorowicz 129 
et al 2016). Thulium oxide nanoparticles in particular, can be also used in the fabrication of an 130 
electrochemical glucose biosensors (Zhang et al 2011). 131 
With growing requirements for improving the shortcomings of radiotherapy and imaging 132 
modalities, much of the research is placed in novel theranostic agents, of which high-Z 133 
nanoparticles are a prominent subject of interest. Thulium and other lanthanide-based 134 
nanoparticles become promising candidates for use in both imaging and radiotherapy. In this 135 
article, we introduce thulium oxide nanoparticles as a potential candidate for image-guided 136 
radiotherapy and this is to our knowledge the first biological application of thulium oxide 137 
nanoparticles. 138 
 139 
METHODS AND MATERIALS 140 
Nanoparticle Preparation and Characterization 141 
Thulium (III) oxide nanoparticles (99.9% trace metals basis) were obtained from Sigma Aldrich.  142 
For initial characterization, a sample of the thulium oxide nanoparticles were analysed with X-143 
ray diffraction (XRD) using a GBC MMA X-ray diffraction system scanning between 20 to 90 144 
degrees to determine structural information and mean particle size. The nanoparticle sample was 145 
exposed to Cu K-alpha radiation with wavelength λ = 1.5418 Å, accelerating voltage 40 kVp and 146 
cathode current 30 mA.   147 
For further confirmation of the nanoparticle size, high-resolution transmission electron 148 
microscopy (HR-TEM) images were obtained. The thulium nano-powder sample was crushed 149 
with mortar and pestle then sonicated in ethanol/water for 40 minutes. The resulting mixture was 150 
then added drop wise onto a Holly carbon mesh covered copper grid.  A JEOL JEM-ARM200F 151 
was used to acquire images with an accelerating voltage of 200 kV.  Scanning electron 152 
microscopic (SEM) images were acquired on a JEOL JSM-7500FA SEM with analysis of 153 
particle size completed in Image J. Pixel length of the particles was measured and then 154 
normalized to a known scale of 100 nm. 155 
 156 
Cell Culture and Nanoparticle Cytotoxicity 157 
9L gliosarcoma cells (obtained from the European Collection of Cell Cultures (ECACC)) were 158 
cultured in T75cm2 flasks containing complete Dulbecco’s modified eagle medium (c-DMEM 159 







































































from Gibco, also including 10% foetal bovine serum (FBS) and 1% penicillin and streptomycin 160 
(PS)) and incubated at 37oC and 5% (v/v) CO2. 161 
Before the addition of nanoparticles or treatment with radiation, 9L gliosarcoma cells were sub-162 
cultured into T12.5cm2 flasks (BD FalconTM) containing complete DMEM. 163 
Thulium oxide nanoparticles were sonicated for 30 mins in DPBS (Dulbecco’s phosphate buffer 164 
solution, Ca2+/Mg2+ free, Gibco BRL, AUS), to separate particles using a Branson Ultrasonic 165 
water bath. Various concentrations (50 - 200 μg/mL) were added to independent T12.5cm2 flasks 166 
24 hrs before the cells reached 95-100% confluence.   167 
Cytotoxicity was determined by a clonogenic assay following the 24 hrs incubation of the 9L 168 
cells with the nanoparticles. Cells were washed with DPBS and trypsinized before seeding into 169 
100 mm petri dishes that contained 10 mL of complete DMEM . Each independent flask was 170 
seeded in triplicate sets corresponding to each treatment including the controls with 0 μg/mL of 171 
nanoparticles. After 15 doubling times, each dish was washed with 5 mL DPBS (with 172 
Ca2+/Mg2+) and stained with solution crystal violet solution of 1:3 ( v/v) in 70% ethanol, from a 173 
2.3%  crystal violet stock (Sigma Aldrich). The surviving colonies of 50 cells or more were 174 
counted and compared with the initial seeding number to determine the plating efficiency (PE). 175 
For each group, the surviving fraction (SF) was calculated by taking the ratio of the PE of the 176 
irradiated cells, by the PE of the non-irradiated control.  177 
  178 
Cell Irradiation  179 
The irradiation of 9L cells was performed at Prince of Wales Hospital (Randwick, NSW, 180 
Australia) using a Nucletron Oldelft Therapax DXT 300 Series 3 Orthovoltage X-ray machine 181 
(Nucletron B.V., Veenendaal, The Netherlands).  T12.5cm2 flasks containing monolayer of 9L 182 
under 6 mm of complete medium were irradiated horizontally at a distance of 50 cm from the 183 
source in full scatter conditions including solid water below and adjacent to cells. X-rays were 184 
generated at 150 kVp with a beam current of 20 mA using inherent filtration of 3 mm Be and 185 
additional 0.35 mm of copper and 1.5 mm of aluminium (HVL= 0.68 mm Cu). These X-rays 186 
were used to irradiate the cells with a dose rate of 0.754 Gy/min for doses ranging from 1 to 8 187 
Gy at 6 mm depth. The beam effective energy was chosen to better target the maximum in mass 188 
energy absorption coefficient thulium oxide relative to water (Figure 1).  189 
9L cells reached 95-100% confluence in T12.5cm2 flasks prior to treatment. Cells were irradiated 190 
with and without thulium oxide nanoparticles that were added in a concentration of 50 μg/mL 24 191 
hrs before irradiation. Clonogenic assay was the radiobiological endpoint to quantify the cells 192 
survival.  193 
The surviving fraction of cells is known to follow a linear quadratic model (Jones et al 2001) 194 
which was fitted to the curve representing the surviving fraction of the cells and its dependence 195 
on the irradiation dose:  196 
        𝑆𝑆 = exp�−(𝛼𝛼 + 𝛽𝛼2)�           (1) 197 







































































Here, D (Gy) is the irradiation dose and α (Gy-1) and β (Gy-2) are parameters representing direct 198 
lethal and sub-lethal damage, respectively. 199 
 200 
 201 
Figure 1:  The ratio of the mass energy absorption coefficients of thulium oxide to water 202 
(Nowotny, 1998) is overlayed with the 150 kVp orthovoltage X-ray energy spectrum produced 203 
by SpekCalc (Poludniowski et al 2009). The X-ray spectrum has been normalized to the most 204 
probable energy count in the spectrum.  205 
 206 
DNA double-strand breaks were revealed by γ-H2AX detection (Ivashkevich et al 2012). 207 
Following the irradiation of the 9L cells in vitro as described above, for the case with and 208 
without nanoparticles, the cells were incubated at 37oC and 5% CO2 (v/v) for 15 mins. After 209 
incubation, 9L cells were fixed with 100% ice-clod methanol for 20 mins and washed with ice-210 
cold DPBS three times. The flasks were treated twice with blocking solution of 3% BSA (bovine 211 
serum albumin) in DPBS. A primary antibody (Mouse anti-phospho-Histone H2AX, at Ser139 212 
clone JBW301) was added 1:500 in 1% BSA DPBS to the cells, and cells were incubated for 2 213 
hours. The cells were washed with DPBS to remove the primary antibody before a secondary 214 
antibody (goat anti-Mouse IgG1 Cross-Absorbed, Alexa Fluor 488) was added 1:500 in 1% BSA 215 
DPBS and incubated for 1 hour in darkness. Lastly, cells were washed in DPBS and images 216 
acquired with a Leica DMi8 fluorescent microscope with a 40x water immersion objective and 217 
20x dry objective. The images were analysed on the Leica Application Suite X (LAS X) software 218 
and ImageJ. 219 
 220 
Flow Cytometric Measurement of Tm2O5 Internalization 221 
Thulium oxide nanoparticles were exposed to cells for 24 hrs in T12.5cm2 flasks, under the 222 
aforementioned cell growth conditions. Cells were washed with DPBS, trypsinized and harvested 223 








































































before centrifuging at 380 g for 5 mins at room temperature. The cells were then washed twice 224 
with DPBS, before resuspension in DPS with a concentration of 106 cells/mL. A BD 225 
LSRFortessa™ flow cytometer analysed the cell sample to measure forward scatter (FSC) and 226 
side scatter (SSC). 227 
 228 
CT Imaging 229 
Thulium nanoparticles of concentrations 0 – 20 mg/mL in DPBS were transferred to 5 mL 230 
Eppendorf tubes and imaged using a Toshiba Asteon CT scanner with 1 mm slice thickness 231 
obtained at 100 kVp energy and 50 mA beam current. Hounsfield units (HU) of each sample 232 
were measured using ImageJ. For comparison with the NPs in solution, expected CT numbers 233 
and electron density of known materials were obtained from a Gammex 467 Tissue 234 
Characterization Phantom. 235 
In vivo experiments were performed in an implanted 9L gliosarcoma tumour in the brain of 5 236 
male Fischer rats. Fischer rats were obtained from the Animal Resource Centre (ARC) in Perth, 237 
Australia, and housed in individually ventilated cages with 3 rodents per cage. At 8 weeks old, 238 
103 9L cells were injected 3.5 mm to the lateral right of the bregma midline intersection and at 239 
5.5 mm depth from the dura into the caudate nucleus of the brain. Rodents were maintained at 2-240 
3% isoflurane during surgery and provided with buprenorphine orally before and after surgery 241 
(0.4 mg/kg). Bupivacaine was administered directly to the scalp before injection (7 mg/kg) as a 242 
local anaesthetic. After 12 days following tumour cell injection, rats were maintained at 2-3% 243 
isoflurane with the same methods for pain relief, for the injection of thulium oxide nanoparticles 244 
into the tumour via the same burr hole at 5.5 mm depth, with a concentration of 20 mg/mL and a 245 
volume of 1.8 μL. CT images were obtained using a Toshiba Asteon CT with 1 mm slice 246 
thickness and beam energy and current of 100 kVp and 200 mA respectively. Images were 247 
acquired at 5 mins, 10 mins, and 25 mins, and from 8 to 24 hrs following nanoparticle injection 248 
to investigate the uptake, distribution, and evacuation of the thulium oxide nanoparticles. All 249 
operative procedures and animal care were in conformity with the guidelines of the Australian 250 
Government code for the care and use of animals for scientific purposes and under the approval 251 
of the University of Wollongong animal ethics committee agreement (AE16/12). 252 
 253 
RESULTS 254 
Nanoparticle Structural Characterization 255 
Structural information and the average size of thulium oxide nanoparticles were measured using 256 
XRD and confirmed with SEM and TEM images. XRD measurements of the thulium oxide 257 
nanopowder are shown in Figure 2. Analysis of peaks present indicate that the material is single 258 
phase and a body-centred cubic structure, which is in good agreement with the PDF card number 259 
10-0350. Further fitting and refinement in MAUD (Materials Analysis Using Diffraction, 260 
Lutterotti et al 1997) gave the crystalline parameter a = (10.495 ± 0.016)Å. The mean crystallite 261 
size was determined to be 42.52 nm using Tracers V6.6.9 which employs Scherrer’s equation 262 






































































(Borchertt et al 2005) to calculate the crystalline size. The size of the nanoparticles was 263 
confirmed to be 40nm – 45nm on average with SEM images. A HR-TEM image shows a sample 264 
of the nanoparticle sizes in Figure 3. 265 
The particle size of thulium oxide nanoparticles may indicate a greater likelihood to be taken up 266 
into cells, following a review of nanoparticle size-dependence on cellular uptake that finds 267 
nanoparticles with sizes of approximately 50 nm are shown to have the greatest potential to be 268 
internalized into the cell (Shang et al 2014). 269 
 270 
Figure 2: Thulium oxide nano-powder XRD, showing major peaks of reflection and 271 
corresponding Miller indices. 272 
 273 
Figure 3: HR-TEM image showing morphology of thulium oxide nanoparticles on a 100 nm and 274 
20 nm scale.  275 









































































Nanoparticle Internalization and Cytotoxicity Measurements 277 
After 24 hrs of incubation with thulium oxide nanoparticles, the cells were analysed to determine 278 
the change in mean side scatter (SSC) and forward scatter (FSC) in the presence of nanoparticles 279 
as an indication of NP uptake by the cells. Figure 4 shows the trend of the SSC dependence on 280 
FSC for the case with and without NPs. Gating has been applied between 35 to 135 from the 281 
FSC area (FSC-A) in order to exclude cell debris. 282 
 283 
Figure 4: Flow cytometric measurements of 9L gliosarcoma cells indicating the internalization 284 
of Tm2O3 cells in terms of SSC magnitude. A control set (a) consisting of 9L cells only is 285 
compared with 9L cells that have been incubated with NPs for 24 hrs at a concentration of         286 
50 µg/mL (b).  287 
While the size of the cell can be related to the forward scatter of light, the amount of side 288 
scattered light from internal components within the cells can be related directly to the number of 289 
internalized nanoparticles within the cell. Figure 4 shows an increase in the mean side scatter due 290 
to the presence of Tm2O3 NPs by 2.35 times the original SSC of the control. From this, we 291 
conclude that nanoparticles have been internalized into the 9L cells. We can attribute this to the 292 
nanoparticle size and the shape. According to Kinnear et al 2016 nanoparticle shape is equally 293 
important in the method and speed of uptake. Smaller spherical particles or those with larger 294 
surface area are often linked to better interaction with the cell membrane and are involved in 295 
clathrin-mediated endocytosis as a form of internalization as well as macropinocytosis for larger 296 
particles. We hypothesise these are the main methods of internalization of these particles along 297 
with more phagocytotic mechanisms which we have observed in 9L. 298 
Toxicity of the NP was assessed by clonogenic survival of 9L cells incubated with different 299 
concentrations of thulium oxide nanoparticles as shown in Figure 5. Mean survival values were 300 
obtained from at least three independent experiments for clonogenic assay experiments. Errors 301 
are calculated from the standard deviation of the mean.  302 









































































Figure 5: Clonogenic survival of 9L gliosarcoma cells exposed to different concentration of 304 
Thulium oxide. 305 
After 24 hrs of exposure, the thulium oxide NPs are internalized into the cell and as a result, 306 
there is a reduction in the cell survival of 9L gliosarcoma. The toxicity towards the 9L cancer 307 
cells tends to increase with concentration until saturation after 100 μg/mL. We believe that this is 308 
due to a limitation in nanoparticle uptake by the cell, that was confirmed with flow cytometry as 309 
a saturation in the mean SSC (data not shown). 310 
 311 
Nanoparticle Radiosensitization 312 
The toxicity data above indicates that a concentration of 50 μg/mL is suitable for the in vitro 313 
radiosensitization experiments. The surviving fraction of 9L cells irradiated at 150 kVp with and 314 
without exposure to NPs at a concentration of 50 μg/mL is shown in Figure 6. The high-Z of 315 
thulium-based nanoparticles (Z = 69) creates a greater likelihood of secondary electron 316 
production on interaction with X-rays which is expected to lead to an enhancement of the 317 
radiation-induced damage to the cells through increased energy deposition. The behaviour of the 318 
cell survival curve can be described by equation 1 above. The parameters of the linear quadratic 319 
model that describe the trend are given in Table 1 for both the case of radiation alone (cells only) 320 
and 9L cells with the addition of thulium oxide nanoparticles.  321 








































































Figure 6: Clonogenic survival of 9L cells irradiated at 150 kVp in the presence (solid line) and 323 
absence (dotted line) of Tm2O3 nanoparticles 324 
 325 
With the addition of the nanoparticles, the linear component of the trend, α, is greater. According 326 
to Jones et al 2001 this corresponds to an increase in the probability per dose of a single radiation 327 
interaction resulting in cell death rather than the necessity of two interactions for a lethal event 328 
that is represented by the quadratic component, β. 329 
The cell sensitivity enhancement ratio (SER) at 10% SF was found to be 1.32 for thulium oxide 330 
nanoparticles when considering the only effect of the radiation enhancement due to the 331 
nanoparticle, and not including intrinsic toxicity. This is comparable with other nano-structured 332 
ceramics considered for radiotherapy such as tantalum oxide, with SER of 1.33 irradiated with 333 
10 MV X-rays (Brown et al 2014). 334 
 335 
Treatment α (Gy-1) β (Gy-2) 
9L Cells Only  0.15 ± 0.03      0.009 ± 0.003 
9L cells with Tm2O3 NPs 0.22 ± 0.02    0.010 ± 0.003 
 336 
Table 1: Summary of Radiobiological parameters, excluding the intrinsic toxicity of the thulium 337 
nanoparticles. 338 
Figure 7 shows an assessment of DNA damage in the form of double-strand DNA breaks (green) 339 
in 9L cells using a Mouse Anti-γ-H2AX IgG1 primary antibody that was introduced to fixed 340 








































































cells 15 mins after irradiation with 150 kVp X-rays in vitro. A single dose of 8 Gy was 341 
considered for the case with and without 50 µg/mL Tm2O3 NPS, and the formation of foci 342 
induced by the secondary Alexa Fluor 488 conjugated goat anti-mouse IgG1 antibody which was 343 
detected at 448 nm using a Leica DMi8 microscope. 344 
 345 
Figure 7: Double-stranded DNA breaks in 9L cells following in vitro irradiation with 8 Gy 150 346 
kVp X-rays, using γ-H2AX (green). 8 Gy without nanoparticles (A) and 8 Gy with thulium 347 
nanoparticles (B), both shown with dry 20x objective in the primary panel and 40x objective in 348 
the sub-panel. 349 
The formation of γ-H2AX foci at 8 Gy tends to increase in the presence of nanoparticles. This is 350 
evident in Figure 7 by the greater occurrence of enlarged foci that corresponds to clustered, more 351 
numerous incidences of double-strand DNA breaks. A greater density of foci was observed to 352 
localize near larger conglomerates of nanoparticles within the cell, leading to larger and denser 353 
foci localized within these regions of the nucleus.  The site-specific nanoparticle enhanced 354 
damage is believed to responsible for the improvement in the 9L cell treatment observed in 355 
Figure 6.  356 
CT Contrast Enhancement 357 
The average CT number (HU) was measured using ImageJ for various concentrations of thulium 358 
oxide in DPBS, and the values were compared with common substances or tissues found in the 359 







































































body (Figure 8). Mean CT numbers of the NP solutions were obtained with ImageJ and errors 360 
represent the standard deviation of the mean. Even low concentrations of the thulium-based 361 
particles (0.25-0.5 mg/mL) will begin to produce contrast above normal brain tissue with a HU 362 
of 27. Above 10 mg/mL, the nanoparticles begin to aggregate. This leads to greater error in the 363 
measured average CT number.  364 
 365 
   366 
Figure 8: Average CT number measured for various concentrations of Tm2O3 nanoparticles, 367 
compared non-linearly to CT numbers of common materials found in the body as provided by a 368 
467 Gammex Tissue Calibration Phantom. 369 
 370 
In a separate in vivo study, thulium nanoparticles (40 µg or 2 µL and concentration of 20 371 
mg/mL) were injected into the caudate nucleus of 9- to 10-week-old Fischer rats in order to 372 
target the brain cancer at day 12 following tumour implantation.  In Figure 9, the evolution of the 373 
nanoparticles’ uptake and position is shown.  374 
In Fig. 9A, the thulium nanoparticles are initially localized around the injection point at 5 mins 375 
following injection. By 10 mins, the nanoparticles have distributed around and inside the tumour 376 
volume (Fig. 9B) and by 25 mins, the nanoparticles are cleared from the tumour (Fig. 9C). The 377 
rodents monitored to 24 hrs showed no trace of the thulium particles. We also observed no 378 
accumulation within the kidneys from injection up until our maximum observing time of 36 hrs 379 
following the nanoparticle injection. Some nanoparticles such as gold or gadolinium are known 380 
to stay in the cancer for longer periods of time (Rogosnitzky et al 2016). We find that the fast 381 
clearance of these nanoparticles from the cancer may be beneficial in reducing the amount of 382 








































































residual high-Z material in the brain. No adverse effects to rodent behaviour or health was 383 
observed up to 3 days following nanoparticle injection. Euthanasia of rats occurred as planned up 384 
to day 17.  385 
 386 
Figure 9: Transverse and sagittal CT images of 3 separate Fischer rats bearing 9L gliosarcoma 387 
brain tumours 5 min (A), 10 min (B), and 25 mins (C) after injection of 2 μL of 20 mg/mL 388 
thulium oxide nanoparticles. Injection route is shown with red arrows, and the tumour region of 389 
interest shown in yellow. 390 
 391 
CONCLUSION 392 
This work presents the first use of thulium-based nanoparticles for biological applications. We 393 
have identified their potential in treatment and diagnosis of radioresistant brain cancers with a 9L 394 
gliosarcoma brain cancer model, both in vitro and in vivo.  395 
We have shown that the Tm2O3 nanoparticles are well internalized into the brain cancer cells. 396 
Their size of 40 nm and spherical or elongated shape can allow the particles a greater likelihood 397 
of interaction with the cell membrane and to be internalized well into cells (Kinnear et al 2017). 398 







































































They do however, show a slight toxicity towards them to induce at maximum 40% survival after 399 
3 weeks following an initial 24 hr exposure with concentrations up to 500 µg/mL.  400 
These thulium nanoparticles are capable of causing radio-sensitization with 150 kVp X-rays with 401 
just 50 µg/mL. Furthermore, high concentrations are not required during CT or radiotherapy, 402 
with only 40 µg capable of producing contrast of the tumour against normal brain with CT. The 403 
faster clearance from the tumour site also may be beneficial for reducing nanoparticle 404 
accumulation in the brain, and the lack of thulium present in the kidneys implies potentially less 405 
danger for the development of NSFs.  406 
Our findings indicate thulium nanoparticles are good candidates for image-guided radiotherapies. 407 
We have successfully shown radiosensitization of tumour cells for a kilovoltage radiation field, 408 
which motivates thulium nanoparticles to be considered for novel kilovoltage therapies treatment 409 
of melanomas (surface cancers) or novel therapies for brain cancer such as synchrotron radiation 410 
treatments, including microbeam radiation therapy (MRT). 411 
 412 
There is need to investigate cancer-specific targeting with thulium oxide nanoparticles. Further 413 
study into nanoparticle induced cancer cell toxicity both in vitro and in vivo is required, as there 414 
is limited evidence here for normal tissue tolerance from the in vivo data. For the time being, the 415 
thulium oxide nanoparticles have no designed cancer cell-specificity. We directly injected the 416 
nanoparticles to the site; however the ability of the nanoparticles to cross the blood brain barrier 417 
must also be assessed. In future, the steps towards personalised medicine can be followed to 418 
modify nanoparticles for the delivery and specific uptake to cancer cells through changes to size, 419 
shape, coating and payload development (Nguyen, 2011). However, tumours of various types 420 
and sizes tend to have different interactions with nanoparticles and require careful consideration 421 
of nanoparticle properties both for diagnostics and treatments. For this reason, further study into 422 
more cell lines both cancerous and normal must be considered in vivo and in vitro to determine 423 
uptake and stability factors for the raw thulium oxide nanoparticle we have investigated here and 424 
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